C4X Discovery Company

C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms Taxonomy3 and Conformetrix that provide a significant competitive advantage when combined with an experienced management team. Taxonomy3 is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. Conformetrix determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. C4XD’s drug discovery engine was further strengthened by the acquisition of technologies from Molplex Ltd, in 2016, which included a software-based system which combines chemoinformatics, computational chemistry and artificial intelligence to optimise the drug discovery process.
Technology: Biomarkers
Industry: Personalized Medicine
Headquarters: Manchester, Manchester, United Kingdom
Founded Date: 2007
Employees Number: Undisclosed
Funding Status: IPO

Visit Website
contact@c4xdiscovery.com
Register and Claim Ownership